Lyra Therapeutics Inc.

LYRA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.49

-$0.83 (-62.88%)

At close: Mar 16, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-62.88%

(1D)

Rating

Updated: Mar 12, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $878.57K

1D Range

0.49 1.33

52W Range

0.49 37.50

Valuation (TTM)

PE -0.14

PB -0.54

EV/EBITDA -0.38

Valuation (NTM)

Forward PE N/A

Forward PEG N/A

Price Target $0.50

Cash Flow

FCF Yield -1612.8%

SBC Adj. FCF Yield N/A

SBC Impact -10.8%

Margins

Gross Margin 50.0%

Operating Margin -5822.5%

FCF Margin -6297.5%

Growth (CAGR)

Revenue 3Y | 5Y 75.3% | N/A

Dil EPS 3Y | 5Y 19.1% | 19.5%

FCF 3Y | 5Y -49.2% | -83.6%

Returns

ROA -75.4%

ROE -1032.8%

ROIC -89.8%

Financial Health

Net Debt

$9.32M

Current Ratio 2.43

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusit...

Sector Healthcare

Industry Biotechnology

Employees 30

IPO Date Apr 30, 2020

Website lyratherapeutics.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.